Edesa Biotech to Present at H.C. Wainwright Global Investment Conference
Edesa Biotech (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced that CEO Par Nijhawan, MD, will present virtually at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. An on-demand presentation will be available from May 24 at 7:00 am ET on the Edesa website. Additionally, senior management will hold one-on-one meetings with attendees. Edesa is developing lead candidates EB05 and EB01 for ARDS and chronic allergic contact dermatitis, respectively.
- None.
- None.
TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022.
An on-demand corporate presentation will be accessible to conference attendees starting on Monday, May 24, 2022 at approximately 7:00 am ET. A webcast of the presentation will also be available by visiting the events section of the Edesa website. The webcast will be accessible on the website for at least 30 days.
Edesa senior management will also be available for one-on-one meetings. Attendees who are interested in meeting with the company should contact their H.C. Wainwright representative or Edesa directly via email at investors@edesabiotech.com.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that Edesa is developing as a treatment for Acute Respiratory Distress Syndrome (ARDS). Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California. Sign up for news alerts. Connect with Edesa Biotech on Twitter and LinkedIn.
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as COVID-19. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Contact
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
investors@edesabiotech.com
SOURCE: Edesa Biotech
View source version on accesswire.com:
https://www.accesswire.com/701931/Edesa-Biotech-to-Present-at-HC-Wainwright-Global-Investment-Conference
FAQ
When will Edesa Biotech present at the H.C. Wainwright Global Investment Conference?
What time will Edesa Biotech's on-demand presentation be available?
How can I access Edesa Biotech's presentation?
What are Edesa Biotech's lead product candidates?
Who can I contact for one-on-one meetings with Edesa Biotech management?
